$1 Trial Offer - Realtime Screener -- Try out our Realtime Product, GetStockIdeas. The advanced screener tool is a momentum trader's dream!

Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
HALO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading HALO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.39%79.771.3%$810.55m
BIIBBiogen Inc.
0.43%308.171.2%$594.94m
AMGNAmgen Inc.
1.02%171.971.1%$507.80m
CELGCelgene Corporation
0.82%108.790.8%$480.49m
MDVNMedivation, Inc.
0.14%80.351.5%$457.05m
REGNRegeneron Pharmaceuticals, Inc.
0.68%402.973.4%$311.23m
ILMNIllumina, Inc.
1.61%172.214.2%$212.71m
ALXNAlexion Pharmaceuticals, Inc.
0.36%129.632.7%$186.81m
BMRNBioMarin Pharmaceutical Inc.
1.32%96.224.2%$183.84m
VRTXVertex Pharmaceuticals Incorporated
0.74%97.092.2%$112.19m
INCYIncyte Corporation
1.17%81.042.5%$106.31m
IONSIonis Pharmaceuticals, Inc.
1.75%30.9011.4%$96.76m
AAgilent Technologies, Inc.
0.13%47.320.9%$93.68m
TSROTESARO, Inc.
1.44%86.4616.2%$88.66m
EXASExact Sciences Corporation
0.74%19.1922.9%$86.20m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel oncology therapies that target the tumor microenvironment. Its investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. Halozyme Therapeutics was founded by Gregory Ian Frost in 1998 and is headquartered in San Diego, CA.